European shares gain as tech stocks rebound; Middle East in focus

European stocks ended mixed: STOXX 600 rose 0.4% to 638.66 as a tech rebound outpaced, with technology up 1.6% (chips: Siltronic +7.4%, Soitec +5.5%, ASML +2.5%). Sentiment stayed guarded on U.S.-Iran escalation and oil (crude marginally lower) after Trump said Iran wanted to “make a deal” amid fresh strikes. Separately, AstraZeneca shares fell 8% after its late-stage nerve disease drug Wainua failed its primary goal, adding company-specific downside to the tape.

Analysis

The semis rebound is more about discount-rate relief and incremental AI optionality than about any single geopolitical headline. If China access to H200-class GPUs is even partially real, the bigger earnings uplift may accrue to the picks-and-shovels chain: substrates, specialty materials, and lithography exposure can see better utilization before headline GPU revenue changes. That makes NVDA tactically constructive, but the cleaner beta may sit in upstream suppliers such as SLOIY and SSLLF if the demand signal broadens beyond one-off shipments.

For Europe, the key mechanism is not the day-to-day move in oil but the lagged margin squeeze on an energy-importing economy if the risk premium persists. A brief pullback in crude is noise; sustained upside would hit transport, chemicals, and cyclicals first, while the energy sector’s relative benefit is too small to offset broader multiple compression if growth expectations roll over. That argues for treating the STOXX bounce as a tradable relief rally rather than confirmation that geopolitical risk has been priced away.

AZN looks like a fundamentals reset, not just a sentiment wobble. Late-stage clinical disappointment typically forces a second leg lower as investors re-cut the probability-weighted pipeline, especially when the asset was supporting long-duration growth assumptions. The contrarian question is whether the market is underestimating how quickly China/export and rate relief can fade: if guidance or policy language disappoints, the recent tech rotation can reverse in days, while the pharma drawdown can take months to stabilize.

Key Decisions for Investors

• Tactically long NVDA for 1-3 months via calls or a small cash equity position; thesis is that any China-access expansion plus dovish rates supports multiple expansion, but fade the trade if export-language tightens or if the stock loses support on a weaker-than-expected AI capex update.
• Prefer a basket long in SLOIY and SSLLF over broad European tech for a 1-3 month trade; these names should outperform if wafer-start expectations improve, but cut exposure if ASML order commentary softens or if the rebound proves purely valuation-driven.
• Short AZN or buy put spreads for 1-3 months versus a large-cap pharma hedge (e.g., NVS/LLY) to isolate trial-failure risk; downside can extend as analysts re-cut pipeline value, but cover if management credibly fills the earnings gap or if the stock stabilizes above the post-event low.
• Do not chase the STOXX 600 bounce outright; use any further strength as an opportunity to short Europe cyclicals/energy-sensitive groups if Brent re-accelerates, since the region’s macro beta to oil is the more durable medium-term risk.
• No actionable edge in DJT from this tape alone; treat it as headline beta only unless there is a separate policy or funding catalyst.